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Background: Manual chest physiotherapy (MCP) techniques involving chest percussion, vibration, and shaking have
long been used in the treatment of respiratory conditions. However, methodological limitations in existing research
have led to a state of clinical equipoise with respect to this treatment. Thus, for patients hospitalised with an
exacerbation of Chronic Obstructive Pulmonary Disease (COPD), clinical preference tends to dictate whether MCP is
given to assist with sputum clearance. We standardised the delivery of MCP and assessed its effectiveness on
disease-specific quality of life.
Methods: In this randomised, controlled trial powered for equivalence, 526 patients hospitalised with acute COPD
exacerbation were enrolled from four centres in the UK. Patients were allocated to receive MCP plus advice on
airway clearance or advice on chest clearance alone. The primary outcome was a COPD specific quality of life
measure, the Saint Georges Respiratory Questionnaire (SGRQ) at six months post randomisation. Analyses were by
intention to treat (ITT). This study was registered, ISRCTN13825248.
Results: All patients were included in the analyses, of which 372 (71%) provided evaluable data for the primary
outcome. An effect size of 03 standard deviations in SGRQ score was specified as the threshold for superiority. The
ITT analyses showed no significant difference in SGRQ for patients who did, or did not receive MCP (95% CI −014
to 019).
Conclusions: These data do not lend support to the routine use of MCP in the management of acute exacerbation
of COPD. However, this does not mean that MCP is of no therapeutic value to COPD patients in specific
circumstances.Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by exacerbations some of which result in increased
cough and excessive sputum production caused by mucus
hyper-secretion and ciliary dysfunction. Manual chest
physiotherapy (MCP) involves external manipulation of
the thorax using percussion and vibration techniques.
Their purpose of these is to intermittently to apply kinetic* Correspondence: j.cross@uea.ac.uk
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reproduction in any medium, provided the orenergy to the chest wall to dislodge bronchial secretions.
The patient then clears these secretions with an expiratory
manoeuvre such as the forced expiration technique (FET).
The assumption underlying the use of MCP is that remov-
ing sputum from the airway improves ventilation
perfusion ratios and thus lung function. However, reviews
of clinical trials report that although airway clearance
techniques may improve sputum expectoration, there is
no high quality evidence of either short or long term value
[1-4].
Methodological limitations inherent in existing studies
include; heterogeneous populations, small samples,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to short term outcomes. Thus, there is clinical equipoise
about whether MCP confers any benefit to patients with
COPD. Consequently, the latest UK guidelines on the
management of COPD call for further research on the
effectiveness of such physiotherapy techniques [5]. This
randomised trial, funded by National Institute of Health
Research Health Technology Assessment, addresses the
limitations of previous research by standardising the de-
livery of MCP and obtaining a sample size sufficient size
to detect long term clinical effectiveness or equivalence
for a patient-orientated, long term outcome.
The full report [6] is available as http://www.hta.ac.uk/
1416. This paper summarises the efficacy of MCP admi-
nistered to patients hospitalised with COPD exacerba-
tion on disease-specific quality of life (QOL) at six
months post intervention.
Methods
Study design and patients
The MATREX trial was a pragmatic, multicentre, rando-
mised controlled trial powered for equivalence. Between
November 21, 2005, and April 30, 2008, 526 patients were
enrolled in four centres in the UK. Patients who were ad-
mitted to hospital with an exacerbation of COPD were
eligible for inclusion in the trial. We excluded patients with
any contraindication to the use of MCP techniques* or with
no evidence of excess sputum production on auscultation. *
Osteoporosis, haemoptysis, bronchial hyper-reactivity,
respiratory system malignancy, raised intracranial pressure,
uncontrolled hypertension (diastolic> 110), pulmonary
embolism, coagulopathy (platelets <50 and/or INR ≥3),
bronchopleural fistula, subcutaneous emphysema and left
ventricular failure as primary diagnosis Our primary object-
ive was to assess the effect, if any, of MCP administered to
patients hospitalised with COPD exacerbation on disease-
specific quality of life at six months post randomisation.
Secondary objectives were to describe the components
of MCP given to patients hospitalised with COPD in-
cluding position selection, duration and frequency of
treatment, and to describe concurrent changes in oxygen
saturation. The protocol was approved by a NHS multi-
centre research ethics committee (reference 06/Q0101/
140). We obtained written informed consent from all
patients.
Procedures
Before the trial, a MCP treatment protocol was devel-
oped with the physiotherapists who would be delivering
the intervention at trial sites (full details of the interven-
tion and control are available in [6].). This reflected con-
sensus on best practice regarding the essential elements
of MCP and clarified potential areas of ambiguity [3,7].
The protocol’s aim was to clearly define the MCP to bedelivered whilst allowing sufficient flexibility to preserve
the profession’s ethos of providing treatment according
to individual need. By consensus the protocol included
the Active Cycle of Breathing Technique (ACBT) [8].
This comprises breathing control, thoracic expansion
exercises and FET. A list of potential adverse events and
associated symptoms [3] was included, along with
recommended actions should any of these occur. The
protocol emphasised defining the circumstances under
which participants in the control arm would receive
MCP, that is, if the physiotherapist or attending phys-
ician felt their condition had deteriorated to the extent
that MCP was warranted. Essentially, these circum-
stances constituted a clinical working definition of
respiratory failure (see consort diagram).
Adult respiratory ward admission lists at participating
hospitals were screened to identify potential study parti-
cipants. Eligible patients were randomised by telephone
using a voice-activated, automated system to stratify by
site (block size six). Trial arm allocation was undertaken
by an individual not involved in the recruitment process
and communicated to participants after their baseline
data had been collected. Patients allocated to the inter-
vention arm were guided to perform ACBT whilst the
physiotherapist delivered MCP. Sputum volume [9,10]
and oxygen saturation [11] are recommended as indica-
tors of physiological impact of MCP. Therefore, oxygen
saturation was monitored with a finger pulse oximeter
and any sputum produced during treatment was col-
lected. Following MCP, the physiotherapist provided the
patient with advice on positioning regarding continu-
ation of ACBT and provided an information sheet
summarising this advice. The patient was asked to con-
tinue to collect all further expectorant produced during
the remainder of their hospital stay. The content, num-
ber and duration of further MCP treatments during
hospitalisation were at the discretion of the physiother-
apist, according to perceived clinical need. For control
arm patients the physiotherapist provided guidance on
the elements of ACBT and advice on suitable positions
to assist with sputum clearance and information sheet
summarising this advice. Their oxygen saturation was
recorded at baseline only and the patient was asked to
collect any expectorant produced during their hospital
stay. For six months post-randomisation, patients re-
admitted to hospital with an exacerbation of their COPD
continued to be treated according to the trial arm to
which they had been allocated.
Outcome measures
The primary outcome measure was change in the Saint
Georges Respiratory Questionnaire (SGRQ) score six
months after randomisation. The SGRQ is specifically
designed for patients with COPD, provides an effective
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exacerbations [12] and is a valid predictor of mortality
[13-16]. Secondary outcome measures included the
Breathlessness Cough and Sputum Scale (BCSS) [17],
the EuroQol (EQ-5D) quality of life index [18] and the
EQ visual analogue scale (VAS) [19] these measures
were recorded during hospitalisation. As some research
suggested lung function measures were useful predictors
of morbidity but of little value in predicting QOL
[20,21] the Medical Research Council (MRC) dyspnoea
scale [22] was included as a baseline indicator of severity
of disease. We followed up patients six months after en-
rolment by postal questionnaire to obtain information
on COPD-specific QOL and other secondary outcomes.
Finally, the number of days spent in hospital during the
full six month study period was obtained retrospectively
for each trial participant by scrutinising hospital data-
bases at the end of follow up.
Statistical analysis
Sample size was based on the primary outcome measure,
SGRQ score. Treating this study as a nonsuperiority trial,
with an effect size of 03 standard deviations (typically
considered small [23]) as the threshold for superiority
then, and assuming a true difference of zero in the popu-
lation (90% power, 5% significance), a total of 233
subjects in each arm were required. To allow for a 15%
drop out rate, we aimed to recruit 275 participants to
each study arm, resulting in a total target sample size of
550 participants. Analyses of accumulating data were
prepared by the trial statistician and reviewed at least
once per year by an independent data monitoring
committee.
Baseline comparability between the treatment arms
was evaluated by summarising and comparing means
and standard deviations (SDs) for continuous variables
or numbers and percentages for categorical variables.
Analyses were based on intention to treat (ITT). 95%
confidence intervals (CI) were estimated for mean differ-
ence between the treatment arms. Equality was regarded
as a difference in effect size of 03 or less in absolute
value; that is, if the upper limit of the 95% CI was less
than 03 and that the lower limit was greater than −03.
The effect size was defined as the mean difference
divided by the pooled, over treatment arm, SD of the
outcome. No adjustment for multiple testing was made.
Analyses of all but one of the outcome measures were
based on an analysis of covariance, with treatment as a
fixed effect and baseline scores and site as covariates.
Analysis of the number of days in hospital was based on
a negative binomial regression model, with treatment as
a fixed effect, site as a covariate and no baseline covari-
ate. A pre-planned subgroup analysis of the primary
outcome by sputum volume (15mls or less versus morethan 15mls) was undertaken by testing for an interaction
between the subgroup and the treatment arm in an
analysis-of-covariance model, with treatment as a fixed
effect and baseline scores, site and subgroup as covari-
ates. All statistical analyses were undertaken using the
STATA (Version 9.1 SE) statistical software package
(STATACORP LP, Texas, USA).
Results
Figure 1 shows the trial profile. The majority of respira-
tory admissions screened at participating sites were ei-
ther for patients who did not have COPD, or the reason
for their admission was not a COPD exacerbation (85%).
The remaining exclusions were due to clinical contra-
indications for MCP (8%) or inability to give informed
consent (7%). 748 patients were approached to partici-
pate in the study, 526 of whom gave their consent (71%).
Nine participants did not receive the intervention to
which they had been allocated. Four patients randomised
to the control arm received MCP for clinical reasons,
four patients allocated to receive MCP declined treat-
ment, and one was discharged before the physiotherapist
had time to treat them. There were five post randomisa-
tion exclusions due to retrospective changes in diagnosis
(3), emergent contra-indication to MCP (1), and
inadvertent repeat recruitment during subsequent hospi-
talisation (1). Other losses to follow up comprised death
during the six month follow up (70), patient-initiated
withdrawal (14), and non-response to questionnaires at
six months post-randomisation (66). This equates to a
retention figure of 71% for the primary outcome meas-
ure at the study end point (372), with similar retention
rates for the two arms. Patients’ baseline characteristics
were well balanced between treatment groups (Table 1).
MCP treatment
Over the three year study period, 257 participants
received 658 sessions of MCP (Table 2). The numbers of
MCP sessions administered to patients ranged between
1 and 25, with the majority receiving 2 or 3 sessions be-
tween randomisation and the end of the six month
follow up. In the majority of sessions (61%) the physio-
therapist selected two different positions in which to
place the patient. Whilst the length of time spent per-
forming MCP varied considerably (1–41 minutes), half
of all sessions lasted between 11 and 19 minutes. With
respect to oxygen saturation, 41% of MCP sessions were
associated with decreasing oxygen level although only
6.6% resulted in a change of 4% or more to a value less
than 90%, 39% resulted in no change and 19% recorded
an increase in oxygen saturation by the end of treat-
ment. This equates to a mean oxygen saturation
pretreatment of 920%, falling to 913% after MCP.




n = 527 
Allocated to MCP arm: n = 261 
Received allocation:  n = 256 
Did not receive allocation:  n = 5b
Lost to Follow-up: n = 72 
Deaths: n = 33
Withdrawals: n = 8
Non response: n = 31
Excluded: n = 6,559 
Failed inclusion criteria: n = 5,877
Refused to participate: n = 221 
Other reasons: n = 461a
Lost to Follow-up: n = 78 
Deaths: n = 37 
Withdrawals: n = 6
Non response: n = 35
Allocated to control arm: n = 266 
Received allocation:  n = 262 
Received MCP for clinical reasons:  n = 4c
Post Randomisation Exclusions: n = 2 
Revised diagnosis: n = 1 
Already recruited: n = 1 
Post Randomisation Exclusions: n = 3 
Revised diagnosis: n = 2 
Emergent exclusion criteria: n = 1 
Number Analysed; n = 186 
Primary Outcome measure (SGRQ) 
Number analysed; n = 186 
Primary Outcome measure (SGRQ) 
Figure 1 Trial profile. a Being discharged (n = 241), no physiotherapist available (n = 73), not under care of Respiratory Consultant (n = 55), lives
out of area (n = 51), already seen by a physiotherapist (41). b No physiotherapist available (1) patient refused treatment (4). c Clinical working
definition of respiratory failure. ALL the following criteria were required to switch arm: i) clinical evidence of sputum retention (e.g. auscultation,
chest x ray). ii) arterial blood gases: pH less than 7.26. iii) arterial blood gases: rising CO2. iv) already receiving controlled oxygen therapy. v) already
receiving other supportive treatment(s).
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of reduced oxygen saturation (−18% to 0%). Adverse
events comprised increased shortness of breath (5), pain
(5), arrhythmia (3), bronchospasm (1), and thoracic
haematoma (1).
Effectiveness analyses
No statistically significant differences were found in
SGRQ total score, either unadjusted or adjusted for
baseline values and hospital site (Table 3). In the un-
adjusted analysis the mean difference was −036 (−431
to 359) and for the adjusted analysis it was 051 (−267
to 369). These equate to effect sizes of −002 (−022 to
019) and 003 (−014 to 019) respectively. With respect
to SGRQ sub-scores, both unadjusted and adjusted CIs
are also within the predefined limits of equivalence.
Adjusted subscore differences comprised; symptom
(087, −350 to 525), activity (−036, −376 to 304) and
impact (043, −329 to 414). No statistically significant
differences were found (unadjusted or adjusted) in anyof the secondary outcome measures (Table 4). Adjusted
differences comprised; 001 (−054 to 056) for BCSS,
−001 (−007 to 006) for EQ5-D and 265 (−235 to
765) for EQ5-D VAS. The mean number of admissions
during the six months following randomisation was 3.89
in the non MCP group and 3.47 in the MCP group. The
corresponding number of nights in hospital was 1595
for the MCP group and 1698 for the non-MCP group.
This equates to an incidence rate ratio (IRR) of 107
(091 to 124). No significant interactions were found in




This study found SGRQ scores at baseline between five and
ten times higher than reported by previous studies in simi-
lar settings suggesting our population had a poorer quality
of life [24,25]. This perhaps reflects recent improvements in
medical treatment with bronchodilators and steroids) that
Table 1 Baseline characteristic of patients enrolled into
the MATREX trial
MCP arm No MCP arm
(n = 258) (n = 264)
N Mean SD N Mean SD
Age (years) 258 69.08 9.85 264 69.58 9.51
SGRQ symptom score 249 79.23 14.42 255 79.61 14.18
SGRQ activity score 249 84.97 15.46 258 84.10 15.87
SGRQ impact score 249 56.58 19.13 258 57.57 18.85
SGRQ – Total score 249 68.94 14.66 255 69.13 14.76
BCSS score 249 6.23 2.11 256 6.44 2.18
Oxygen Saturation (%) 254 92.33 3.67 252 92.77 5.03
Sputum (mls) 240 8.17 11.09 255 7.89 9.63
EQ-VAS 196 44.95 21.03 202 46.64 21.42
EQ-5D Score 199 0.45 0.32 202 0.43 0.36
n/N % n/N %
Female 115/258 44.57 109/264 41.29
Current smoker 43/221 19.46 49/224 21.88
Ex smoker 175/221 79.19 172/224 76.79
Never smoked 3/221 1.36 3/224 1.34
Sputum >15 mls 38/240 15.83 42/255 16.47
JPH 62/258 24.03 65/264 24.62
NNUH 77/258 29.84 79/264 29.92
QEH 37/258 14.34 36/264 13.64
UHA 82/258 31.78 84/264 31.82
MRC score
1 0/250 0.00 1/255 0.39
2 11/250 4.40 14/255 5.49
3 27/250 10.80 27/255 10.59
4 68/250 27.20 75/255 29.41
5 144/250 57.60 138/255 54.12
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is more severe. Anecdotal evidence suggests there has been
an increasing trend for admitted patients to be very sick
with end stage disease and multiple co-morbidities. How-
ever, the study death rate of 13% is consistent with others
reported in the literature [24,26].MCP treatment protocol
The MCP treatment protocol was designed both to re-
flect current practice and to comply with the best avail-
able research evidence at the time. Physiotherapists’ high
level of adherence indicates that they found this protocol
acceptable and so our aim to standardise the study inter-
vention was achieved. With respect to the short term
physiological effect of MCP, we found a mean reduction
in oxygen saturation of 07%.However there was a wide variation in individual
responses, ranging from −18% to 15%. Whilst MCP has
been linked to clinically significant falls in oxygen satur-
ation [27] interpretation of our results is difficult be-
cause treatment did not occur in isolation. The selection
of particular positions and changes to position could
also have altered lung ventilation/perfusion ratios. None-
theless, our findings do suggest that oxygen de-
saturation is more common than previously reported,
supporting the routine use of oxygen saturation moni-
toring during MCP, both to identify patients who need
oxygen and assess the effect of the MCP itself. The rela-
tively high baseline SGRQ scores found amongst our
trial participants indicate a significant level of impair-
ment and there is little robust information to guide clini-
cians on the risk of significant de-saturation in this
patient group.
Recruitment and retention
The study successfully recruited 526 individuals in from
4 sites in just over 29 months, with the primary outcome
recorded for 372 individuals. This was less than our tar-
get of 466, hence in order to ensure that we minimised
our chance of a type II error we carried out a sensitivity
analysis by imputing the incomplete data using multiple
chain equations in STATA using all available baseline
data in order to base the analyses on all 522 individuals.
The results of this were in keeping with the conclusions
of the presented analysis. Hence, it is unlikely that the
results are due to a type II error.
The effectiveness of MCP treatment
This study found no gain in long term respiratory quality of
life when MCP was included in the physiotherapy manage-
ment of acute exacerbation of COPD. After adjusting for
baseline, the mean difference in SGRQ score at six months
was within our pre-specified limits of equivalence. This
finding also excludes the minimum clinically important dif-
ference (MCID) of four points in SGRQ score [28,29] al-
though it should be noted that the trial was not powered to
demonstrate equivalence for this measure. Differences in
SGRQ sub-scores also indicate statistical equivalence.
Whilst the upper limits of the 95% CI for symptom and im-
pact sub-score did achieve the MCID these differences not
statistically significant (p=070 and 082 respectively). The
choice of a quality of life measure as the primary outcome
to measure effectiveness is unusual as previous literature
has focused on short term physiological measures such as
FEV1, oxygen saturation and sputum volumes as measures
of efficacy. However short term efficacy may be of little
value to the patient unless there is longer term effective-
ness. In order to assess this longer term effectiveness QOL
is an appropriate patient reported outcome measure. Meas-
ure related to short term efficacy such as oxygen saturation
Table 2 Summary of MCP Treatment parameters (N= 658 sessions)
MCP treatment parameter Min Max Mean/median Breakdown of parameter: N (% total sessions)
Number of MCP
sessions/patient
1 21 2.53/2 N. sessions
per patient
N. patients N. sessionsa % Total
sessions(total = 257) (total = 658)
1 97 97 14
2 70 140 21
3 47 141 22
4 20 80 12
5 6 30 5
6 3 18 3
7 5 35 5
8 or more 9 117 18
Number of positions/session 1 3 1.91/2 1 position: 248 sessions (38%)
2 positions: 404 sessions (61%)
3 positions: 6 sessions (1%)
Time taken per session 1 41 11.9/11 Less than 5 minutes: 14 sessions (2%)
5− 10 minutes: 266 sessions (40%)
11− 19 minutes: 323 sessions (49%)
20− 25 minutes: 44 sessions (7%)
26 or more minutes: 11 sessions (2%)
O2 saturation (%) - immediately
prior to MCP
74 100 92.0/93 Less than 85%: 30 (4%)
85% to 89%: 111 (17%)
90% to 94%: 413 (63%)
95% to 100%: 98 (15%)
O2 saturation (%) --lowest during MCP 69 99 91.3/92 Less than 85%: 44 (7%)
85% to 89%: 130 (20%)
90% to 94%: 385 (58%)
95% to 100%: 93 (14%)
O2 saturation (%) - change during MCP −18 +13 −0.7/0 Drop in O2 saturation: 268 (41%)
No change in O2 saturation: 258 (39%)
Increase in O2 saturation: 126 (19%)
Deviations from MCP Treatment Protocol N= 258 One position only: 248 (38%)
O2 saturation not recorded: 6 (<1%)
Patient declined treatment: 4 (<1%)
Alternative positions selected N= 44 Upright: 31 (5%)
Leaning forward: 10 (2%)
Flat on back: 3 (<1%)
a Numbers quoted comprise the total number of sessions received by trial participants between 1st December 2005 and 30th October 2008. This includes MCP
given at subsequent admissions during the 6 month follow up.
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ondary outcome measures yielded statistically significant
results. Although the incident rate ratio for the number of
nights in hospital indicates that, on average, the non-MCP
group spent 7% longer in hospital, this too was not signifi-
cant (p=042).
MCP versus ACBT
There is evidence that MCP is used less than before
whilst the active cycle remains the treatment of choice. A
survey of physiotherapists working in UK acuteadmitting hospitals [26] asked which physiotherapy treat-
ments they employed to treat COPD exacerbations and
with what frequency (n = 146). More than three quarters
(77%) responded that they did treat this patient group
and that ACBT was employed in the vast majority of
cases (88%). A significantly smaller proportion reported
using manual techniques “always or often” in conjunc-
tion with ACBT (26% vibrations, 8% percussion, 11%
shaking) whereas 66% reported using MCP techniques
“sometimes or rarely”. In contrast A survey of Canadian
therapist found that less than half used manual
Table 3 Primary Outcome measure results
MCP arm No MCP arm Unadjusted analysis no MCP
versus MCP
Adjusted analysis a no MCP
versus MCP
N Mean SD N Mean SD Mean
difference





186 63.88 19.05 186 63.52 19.68 −0.36 −4.31,3.59 0.8573 0.51 −2.67,3.69 0.753
Effect size −0.02 −0.22,0.19 0.03 −0.14,0.19
SGRQ -Symptom
score
186 68.38 23.13 186 68.40 23.01 0.02 −4.68,4.73 0.9925 0.87 −3.50,5.25 0.695
Effect size 0.00 −0.20,0.21 0.04 −0.15,0.23
SGRQ -Activity
score
188 82.49 18.81 187 80.91 19.74 −1.58 −5.50,2.34 0.4279 −0.36 −3.76,3.04 0.836
Effect size −0.08 −0.29,0.12 −0.02 −0.20,0.16
SGRQ -Impact
score
188 51.53 22.58 187 51.60 22.50 0.07 −4.51,4.65 0.9752 0.43 −3.29,4.14 0.822
Effect size 0.00 −0.20,0.2 0.02 −0.15,0.18
a difference adjusted to take into account baseline value and hospital site.
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bilisation and exercise training [30]. The present study
employed ACBT in both trial arms comparing ACBT
plus or minus MCP. Thus there remains a need to evalu-
ate the effectiveness of ACBT compared to no ACBT.
The high level of adherence to the MCP treatment proto-
col used in this trial suggests it would be acceptable
amongst the profession in usual practice. There is also a
need to evaluate the mode of delivery for ACBT. Our
results suggest that a short teaching session on ACBT
and several sessions of ACBT performed with the sup-
port from a physiotherapist have the same effect on QOL
after six months. Given recent trends of increasingly se-
vere hospital admissions for COPD, future research
regarding physiotherapy interventions with this patient
population should focus on examining the effectiveness
of ACBT provided in primary care settings.
Conclusions
Implications for healthcare
The National Strategy for COPD in England was devel-
oped by the Department of Health and went toTable 4 Secondary Outcome Measures results
MCP arm No MCP arm
N Mean SD N Mean SD
d
BCSS 175 5.60 2.96 179 5.66 2.84
Days in hospital b 258 15.95 16.49 264 16.98 18.04
EQ-VAS 167 51.29 20.97 173 52.25 19.65
EQ-5D Score 209 0.48 0.33 207 0.45 0.35
a difference adjusted to take into account baseline value and hospital site.
b analysed with a negative binomial regression model.
c Incidence Rate Ratio (IRR).consultation early in 2010. This was the first national
strategy for a respiratory disease in England. One of its
defined remits is to ensure that when someone is admit-
ted to hospital, the time is used effectively to avoid re-
current hospitalisation [31]. The results of the MATREX
trial do not lend support to the routine use of MCP in
the management of acute exacerbation of COPD this is
in line with two recent systematic reviews published
since the completion of this study. The pragmatic stance
adopted throughout our investigation and the inclusion
of both urban and rural sites with a broad range of
socioeconomic characteristics means our findings are
likely to have a high degree of generalisibility. It is pos-
sible that MCP may have therapeutic value to subgroups
of COPD patients in specific circumstances but this has
not yet been shown.
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